Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PB1 is a highly-effective intracellular disulfide reducing agent with notable attributes such as excellent cell permeability, the capacity to generate a substantial intracellular concentration gradient, and remarkable stability. It serves as a borane-protected TCEP (tris(2-carboxyethyl)phosphine) analogue. PB1 demonstrates the potential to enhance the survival of retinal ganglion cells following axotomy in vitro at concentrations in the nanomolar and picomolar range. Consequently, PB1 has proven instrumental in the study of neuroprotective properties[1][2][3].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 2,120 | 5日内发货 | ||
5 mg | ¥ 3,160 | 5日内发货 | ||
25 mg | ¥ 11,400 | 6-8周 | ||
50 mg | ¥ 14,900 | 6-8周 | ||
100 mg | ¥ 23,700 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,470 | 5日内发货 |
产品描述 | PB1 is a highly-effective intracellular disulfide reducing agent with notable attributes such as excellent cell permeability, the capacity to generate a substantial intracellular concentration gradient, and remarkable stability. It serves as a borane-protected TCEP (tris(2-carboxyethyl)phosphine) analogue. PB1 demonstrates the potential to enhance the survival of retinal ganglion cells following axotomy in vitro at concentrations in the nanomolar and picomolar range. Consequently, PB1 has proven instrumental in the study of neuroprotective properties[1][2][3]. |
体外活性 | PB1 produces a robust activation of the BDNF effector ERK1/2. PB1 promotes RGC survival[1]. |
体内活性 | PB1 (150 μM; intraocular injection; 1 week) attenuates the loss of both RGC (retinal ganglion cells) soma and axons in experimental glaucoma[1].PB1 protects RGC soma in experimental glaucoma. PB1 single dose limits the biological activity in vivo. PB1 attenuates the loss of both RGC soma and axons in experimental glaucoma. PB1 (0.001~100 μM; 72 hours) is effective at rescuing acutely axotomized retinal ganglion cells[1][2]. |
分子量 | 296.11 |
分子式 | C14H22BO4P |
CAS No. | 188714-28-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (337.71 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3771 mL | 16.8856 mL | 33.7712 mL | 84.4281 mL |
5 mM | 0.6754 mL | 3.3771 mL | 6.7542 mL | 16.8856 mL | |
10 mM | 0.3377 mL | 1.6886 mL | 3.3771 mL | 8.4428 mL | |
20 mM | 0.1689 mL | 0.8443 mL | 1.6886 mL | 4.2214 mL | |
50 mM | 0.0675 mL | 0.3377 mL | 0.6754 mL | 1.6886 mL | |
100 mM | 0.0338 mL | 0.1689 mL | 0.3377 mL | 0.8443 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PB1 188714-28-5 PB 1 PB-1 Inhibitor inhibitor inhibit